|
| |
PDL BioPharmaPDL BioPharma is a leader in the discovery, development and marketing of innovative therapies for serious or life-threatening illnesses, commercially focused on the acute care, hospital setting. Our therapeutic emphasis is on the areas of hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer . Developing and commercializing innovative therapies for serious or life-threatening illnesses — this is what PDL BioPharma is all about. With a unique focus on the acute care, hospital-based setting, our research, development and commercial teams are working to bring new therapies to physicians and patients that we hope will improve and save lives. Today, our commercial products — Cardene I.V., Retavase and IV Busulfex — are helping patients with serious medical illnesses, while our research and development teams strive to bring important innovative new therapies to the forefront of tomorrow's patient care.
| Contact Details: |
| 34801 Campus Drive |
| Fremont |
| California |
| 94555 |
| United States of America |
| Tel: | 510-574-1400 |
| Fax: | 510-574-1500 |
| Email: | tpearce@pdl.com |
| WWW: | www.pdl.com/
|
|
Loading...
|
Recent Publications by PDL BioPharma: |  |
Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.
Humanization and modification of the Fc region of anti-human CD3 mAbs have... | 30th May, 2009
| PDL BioPharma 1400 Seaport Blvd Redwood City, CA 94063, USA.
| J Neuroimmunol. 2009 May 22.
DOI Direct Link |
Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies.
Several low- or non-FcR binding anti-human CD3 monoclonal antibodies have... | 26th February, 2009
| Research Department, PDL BioPharma, Redwood City, California 94063, USA.
| Immunol Invest. 2009;38(1):76-92.
DOI Direct Link |
NS0 cell damage by high gas velocity sparging in protein-free and cholesterol-free cultures.
Recent developments in high cell density and high productivity fed-batch... | 19th November, 2008
| Process Sciences and Engineering, PDL BioPharma, Inc., 1400 Seaport Blvd,
| Biotechnol Bioeng. 2008 Nov 1;101(4):751-60.
DOI Direct Link |
Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.
Angiogenesis, the process by which new blood vessels form from existing... | 10th June, 2008
| PDL Biopharma, Inc., 34801 Campus Drive, Fremont, CA 94555, USA.
| Invest New Drugs. 2008 Feb;26(1):7-12. Epub 2007 Sep 1.
DOI Direct Link |
A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.
BACKGROUND: Integrins are important adhesion molecules that regulate tumor... | 29th March, 2008
| Department of Research, PDL Biopharma, Inc,, Fremont, CA 94555, USA.
| J Transl Med. 2007 Nov 27;5:61.
DOI Direct Link |
→View more PDL BioPharma research publications. |
Press Releases on PDL BioPharma:
|
 |
| PDL BioPharma Announces Record Date for October 1 Dividend Payment |
10th June, 2009 |
PDL BioPharma, Inc. |
INCLINE VILLAGE, Nev., June 10 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that all shareholders owning shares of PDL on September 17, 2009, will be paid a
|
| PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million |
8th June, 2009 |
PDL BioPharma, Inc. |
INCLINE VILLAGE, Nev., June 8 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the second quarter ended June 30,
|
| PDL BioPharma to Present at the 8th Annual JMP Securities Research Conference on May 18, 2009 |
12th May, 2009 |
PDL BioPharma, Inc. |
INCLINE VILLAGE, Nev., May 12 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer,
|
| PDL BioPharma Announces First Quarter 2009 Financial Results |
7th May, 2009 |
PDL BioPharma, Inc. |
- Revenues From Continuing Operations Increase 25 Percent to $62.6 Million -
- Conference Call Today at 4:30 p.m. Eastern Time -
INCLINE VILLAGE, Nev.,
|
| PDL BioPharma To Announce First Quarter 2009 Financial Results and Hold Conference Call May 7, 2009 |
30th April, 2009 |
PDL BioPharma, Inc. |
INCLINE VILLAGE, Nev., April 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hold a conference call and webcast on Thursday, May 7 at 4
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 681 times since April 2007, the link to the organisation's website has been followed 68 times Recent Search Terms used to find this page: pdl.com | 2009 pdl redwood city home | email pdl com | pdl.com | PDL biopharma AND email | biopharma companies, california | pdli july 2007 | pdl finance | PDL BioPharma | PDL BioPharma | . Search for more companies in Fremont Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for PDL BioPharma |
